Abnormal platelet reactivity in men with premature coronary heart disease

D A McGill1, N G Ardlie

  • 1Department of Cardiology, Woden Valley Hospital, Australia.

Coronary Artery Disease
|November 1, 1994
PubMed

Insights

Platelets in men with premature coronary heart disease (CHD) are larger and aggregate faster, particularly with adrenaline. This heightened platelet aggregation correlates with the severity of coronary artery disease (CAD) lesions.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Platelet Biology

Background:

  • Platelet hyper-reactivity may predispose individuals to cardiac events.
  • This study investigates the link between in-vitro platelet aggregation and coronary artery disease (CAD).

Purpose of the Study:

  • To evaluate the relationship between in-vitro platelet aggregation and angiographically defined coronary artery disease (CAD).

Main Methods:

  • A case-control study compared 53 men with premature coronary heart disease (CHD) to 48 age- and sex-matched controls.
  • In-vitro platelet aggregation was measured using adrenaline, adenosine diphosphate (ADP), and collagen.
  • Coronary angiography assessed the extent and severity of arterial wall involvement and discrete lesions.

Main Results:

  • Patients with CHD had larger platelets and significantly faster adrenaline-induced aggregation rates compared to controls.
  • Adrenaline-induced platelet aggregation correlated with the number and severity of obstructive coronary lesions.
  • No association was found between platelet reactivity and the overall extent of coronary artery disease.

Conclusions:

  • Premature CHD is associated with larger platelets and increased aggregation, especially with adrenaline.
  • Enhanced adrenaline-induced platelet aggregability predicts CAD lesion severity, suggesting a role in localized obstructive lesion formation.
  • Platelets may contribute to the development of localized obstructive lesions in coronary arteries, potentially leading to acute coronary events.
Abstract

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...